Dwivedi Anamika, Mehta Anurag, Solanki Poonam
Department of Research, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Indian J Pathol Microbiol. 2015 Oct-Dec;58(4):453-8. doi: 10.4103/0377-4929.168886.
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma in Indian population. The disease could be divided into the prognostically important subtypes, germinal center B-cell (GCB)-like and activated B-cell-like, using gene expression profiling (GEP). The molecular subtype as defined by GEP could also be predicted by using immunohistochemistry (IHC) based algorithms using three biomarkers CD10, BCL-6, and multiple myeloma oncogene-1 (MUM1). It has been confirmed that patients belonging to the GCB subtype have a better outcome and survival than those belonging to the second subtype. The present study was conducted to study the prevalence of these two subgroups and their correlation with survival of the patients.
A total of 83 patients of DLBCL were included in the study. Hematoxylin- and eosin-stained sections were prepared from the paraffin-embedded tissue blocks. The staining for all the three antibodies was considered positive when more than 30% cells were stained with the respective antibody.
The results showed that 44 patients (53%) had GCB immunophenotype and 39 patients (47%) had non-GCB phenotype. However, no statistically significant difference in overall and disease-free survival was noted between the subgroups.
This study demonstrated that frequency of GCB subtype of DLBCL is significantly higher than the non-GCB subtype, and the non-GCB immunophenotype has better relapse-free survival 78% (standard error = 0.10) at the end of 3 years, while GCB has 56% (standard error = 0.23). Further studies should be performed with larger number of patients to show difference in clinical outcome between GCB and non-GCB subgroups.
弥漫性大B细胞淋巴瘤（DLBCL）是印度人群中最常见的非霍奇金淋巴瘤类型。利用基因表达谱（GEP），该疾病可分为具有重要预后意义的亚型，即生发中心B细胞（GCB）样和活化B细胞样。通过使用基于免疫组织化学（IHC）的算法，利用三种生物标志物CD10、BCL-6和多发性骨髓瘤癌基因-1（MUM1），也可以预测由GEP定义的分子亚型。已经证实，属于GCB亚型的患者比属于第二种亚型的患者具有更好的预后和生存率。本研究旨在探讨这两个亚组的患病率及其与患者生存率的相关性。
本研究共纳入83例DLBCL患者。从石蜡包埋的组织块制备苏木精和伊红染色切片。当超过30%的细胞被相应抗体染色时，所有三种抗体的染色均被视为阳性。
结果显示，44例（53%）患者具有GCB免疫表型，39例（47%）患者具有非GCB表型。然而，各亚组之间在总生存期和无病生存期方面未观察到统计学上的显著差异。
本研究表明，DLBCL的GCB亚型频率显著高于非GCB亚型，非GCB免疫表型在3年末具有更好的无复发生存率，为78%（标准误=0.10），而GCB为56%（标准误=0.23）。应进行更多患者的进一步研究，以显示GCB和非GCB亚组之间临床结局的差异。
